RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,621,494 | +108.0% | 342,679 | +103.1% | 0.00% | – |
| Q2 2023 | $1,260,376 | +11.9% | 168,725 | -0.1% | 0.00% | – |
| Q1 2023 | $1,126,796 | -59.6% | 168,935 | -53.3% | 0.00% | -100.0% |
| Q4 2022 | $2,790,210 | +1323.6% | 361,895 | +1859.9% | 0.00% | – |
| Q3 2022 | $196,000 | +378.0% | 18,465 | +270.3% | 0.00% | – |
| Q2 2022 | $41,000 | -16.3% | 4,986 | -28.0% | 0.00% | – |
| Q1 2022 | $49,000 | -98.9% | 6,927 | -97.3% | 0.00% | -100.0% |
| Q4 2021 | $4,440,000 | +171.2% | 259,222 | +264.4% | 0.00% | 0.0% |
| Q3 2021 | $1,637,000 | +6196.2% | 71,143 | +10063.3% | 0.00% | – |
| Q2 2021 | $26,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |